Glenmark launches Clindamycin Phosphate Foam, 1%

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin2 Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million

Powered by Capital Market - Live News